Circadian biomarkers in sleep disturbances linking menopause and Alzheimer’s disease: shared pathways and therapeutic perspectives

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that disproportionately affects women. A significant number of individuals with AD experience sleep disruptions, as do many women navigating menopause, a transition marked by a decline in sex hormones. These shared sleep disturbances are primarily linked to the disruption of circadian rhythms. Although individual research on circadian dysfunction in AD and menopause is extensive, a critical gap remains in understanding the integrated role of circadian biomarkers across both conditions. To address this gap, we conducted a comprehensive review of relevant articles from MEDLINE (via PubMed), Scopus, and Web of Science. Our primary research question was to investigate how menopause may contribute to AD pathogenesis through circadian dysfunction and related sleep disturbances. A review of articles revealed that four circadian biomarkers are altered in both conditions: reduced melatonin secretion, elevated orexin levels, hypertension, and changes in core clock genes. We proposed that alterations in these biomarkers during menopause, driven by age-related changes and the decline of estrogen and progesterone, may potentially increase the risk of developing AD or accelerate the progression of pre-existing AD and related sleep disturbances. Based on this hypothesis, we also identified potential shared therapeutic approaches that may target these pathways. These include menopausal hormone therapy and chronotherapeutic interventions such as melatonin supplementation, orexin receptor antagonists, and light therapy. This review underscores the need for further research into the integrated role of circadian disruption in the link between menopause and AD.

Authors

Institutions

Publication Details

Journal
BMC Women s Health
Published
2026-11-19
DOI
https://doi.org/10.1186/s12905-026-05138-y
Primary Topic
Circadian rhythm and melatonin
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Circadian biomarkers in sleep disturbances linking menopause and Alzheimer’s disease: shared pathways and therapeutic perspectives

Fardin Nabizadeh, Mana Jameie, Melika Jameie, Seyed Behnamedin Jameie et al.
BMC Women s Health
Circadian rhythm and melatonin
article

Circadian biomarkers in sleep disturbances linking menopause and Alzheimer’s disease: shared pathways and therapeutic perspectives

Fardin Nabizadeh, Mana Jameie, Melika Jameie, Seyed Behnamedin Jameie, Setareh Nejadrostam
article en

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that disproportionately affects women. A significant number of individuals with AD experience sleep disruptions, as do many women navigating menopause, a transition marked by a decline in sex hormones. These shared sleep disturbances are primarily linked to the disruption of circadian rhythms. Although individual research on circadian dysfunction in AD and menopause is extensive, a critical gap remains in understanding the integrated role of circadian biomarkers across both conditions. To address this gap, we conducted a comprehensive review of relevant articles from MEDLINE (via PubMed), Scopus, and Web of Science. Our primary research question was to investigate how menopause may contribute to AD pathogenesis through circadian dysfunction and related sleep disturbances. A review of articles revealed that four circadian biomarkers are altered in both conditions: reduced melatonin secretion, elevated orexin levels, hypertension, and changes in core clock genes. We proposed that alterations in these biomarkers during menopause, driven by age-related changes and the decline of estrogen and progesterone, may potentially increase the risk of developing AD or accelerate the progression of pre-existing AD and related sleep disturbances. Based on this hypothesis, we also identified potential shared therapeutic approaches that may target these pathways. These include menopausal hormone therapy and chronotherapeutic interventions such as melatonin supplementation, orexin receptor antagonists, and light therapy. This review underscores the need for further research into the integrated role of circadian disruption in the link between menopause and AD.

BMC Women s Health
Iran University of Medical Sciences (IR), Cardiovascular Diseases Research Institute (IR), Tehran University of Medical Sciences (IR)
Circadian rhythm and melatonin
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon